Phase 4 N=19 Stereotactic Body Radiotherapy for Head and Neck Tumors
Squamous Cell Carcinoma of the Head and Neck · Nasopharyngeal Carcinoma · Salivary Gland Cancer
Primary: Local Control Rate — 1; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=21 Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
Head and Neck Cancer · Head and Neck Neoplasms
Primary: Number of Participants Who Experience a Pathologic Complete Response (pCR) — 0; 0 Participants
Phase 2 N=72 Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
N/A N=7 Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Phase 2 N=72 Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
Head and Neck Cancer · Carcinoma, Squamous Cell · Neoplasms, Oral
Primary: Number of Patients With Solitary Elective Volume Recurrence — 0 Participants
N/A N=12 Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
Head and Neck Cancer
Primary: Duration of Local Control — 4.6 number of months to local failure
Phase 1 N=14 Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Squamous Cell Carcinoma of the Head and Neck · Carcinoma of the Head and Neck
Primary: Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling — 0; 4; 0; 0 Lymph Nodes
Phase 2 N=20 Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
Lip and Oral Cavity Squamous Cell Carcinoma · Oral Cavity Verrucous Carcinoma · Precancerous Condition
Primary: Comparison Between Treatment Groups of the Within-patient Change in MVD Score Following Treatment Initiation
Phase 2 N=79 Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients
Head and Neck Squamous Cell Carcinoma
Primary: Major Pathologic Response — 22 Participants
Phase 2 N=22 Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma · Recurrent Metastatic Squamous Neck Cancer With Occult Primary · Recurrent Squamous Cell Carcinoma of the Hypopharynx
Primary: Objective Tumor Response Rate (Complete Response [CR] and Partial Response [PR]) Using RECIST Criteria — 6.7; 0 percentage of participants
Phase 2 N=22 Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Phase 2 N=60 Treatment of Head & Neck Cancer With Chemotherapy and Radiation
Head and Neck Cancer
Primary: Two-Year Progression Free Survival (PFS) Probability, the Percentage of Patients Estimated to be Alive Without Worsening of Their Disease Two Years After Beginning…
N/A N=9 Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer
Malignant Melanoma · Head and Neck Cancer
Primary: Tissue and Hematopoietic Stem Cell Collection — 8 Participants
Phase 2 N=33 Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
Head and Neck Cancer · Cancer of the Pharynx · Cancer of the Larynx
Primary: Llocoregional Recurrence — 27 Participants
Phase 2 N=27 Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery
Parotid Neoplasm · Thyroid Neoplasms · Head and Neck Neoplasms
Primary: Safety - The Number of Patients With ALM-488 Related Adverse Events — 0; 0; 0; 0 Participants
Phase 3 N=743 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer
Head and Neck Cancer
Primary: Overall Survival (Percentage of Participants Alive) — 64.3; 70.3 percentage of patients — p=0.180
Phase 2 N=12 A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
Squamous Cell Carcinoma of the Head and Neck
Primary: Percentage of Participants With Pathologic Complete Response (pCR) as Determined by Local Pathologic Review — 16.7; 50.0 percentage of participants
Phase 2 N=18 The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants
Phase 2 N=3 Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer
Head and Neck Squamous Cell Carcinoma · Squamous Cell Carcinoma of the Head and Neck (SCCHN) · Head and Neck Cancer
Primary: Detection of Malignancy in Excised Lymph Nodes by Pathology or Labeling With Lymphoseek and/or Panitumumab-IRDye800 — 10; 5; 3; NA Lymph nodes
Phase 2 N=39 Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants
N/A N=16 Image-Guided Adaptive Radiotherapy for in Detecting Tumors During Treatment in Patients With Head and Neck Cancer
Head and Neck Cancer
Primary: Differences of Calculated Set up Errors of 2 mm Between the Different Imaging Technologies — -1.2; -0.8; -1.8; -1.5 mm — p=1.00
Phase 3 N=145 Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
Head and Neck Cancer
Primary: Overall Survival — 73; 78 percent of patients
Phase 2 N=7 Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
Head and Neck Cancer · Squamous Cell Cancer
Primary: Participant Response Rate — 7 Participants
Phase 2 N=67 Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Cancer of Head and Neck · Head and Neck Cancer · Neoplasms, Head and Neck
Primary: Locoregional Recurrence Rates in Cohorts 1 and 2 — 2; 2 Participants
Phase 2 N=33 F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
Mouth Neoplasms · Oropharyngeal Neoplasms · Laryngeal Neoplasms
Primary: Efficacy of Mean Pre-therapy FLT Uptake (SUVmean) in Predicting Progression Free Survival (PFS) — 4.23 standardized uptake value (SUV) — p=0.08
N/A N=23 A Study Using Cone Beam CT for Head and Neck Cancer
Head and Neck Cancer
Primary: Rate of Movement of Normal Tissue
N/A N=11 Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck
Head and Neck Cancer
Primary: Number of Participants With Any Adverse Device Effects Considered Attributable to AuroShell Particle Administration — 2; 2; 0 participants
Phase 2 N=31 Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
Head and Neck Cancer
Primary: Overall Response — 28 Participants
Phase 2 N=64 Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: Objective Response Rate — 37.5; 5.9; 0; 16.7 percentage of patients
Phase 2 N=74 Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer
Head and Neck Cancer
Primary: Event-free Survival Rate at 1 Year — 0.79 proportion of patients